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Food allergy is a potential risk associated with use of transgenic
proteins in crops. Currently, safety assessment involves consideration of the source of the introduced protein, in silico amino acid
sequence homology comparisons to known allergens, physicochemical properties, protein abundance in the crop, and, when
appropriate, specific immunoglobulin E binding studies. Recently
conducted research presented at an International Life Sciences
Institute/Health and Environmental Sciences Institute–hosted workshop adds to the scientific foundation for safety assessment of
transgenic proteins in five areas: structure/activity, serum screening,
animal models, quantitative proteomics, and basic mechanisms. A
web-based tool is now available that integrates a database of
allergenic proteins with a variety of computational tools which could
be used to improve our ability to predict allergenicity based on
structural analysis. A comprehensive strategy and model protocols
have been developed for conducting meaningful serum screening, an
extremely challenging process. Several animal models using oral
sensitization with adjuvant and one dermal sensitization model have
been developed and appear to distinguish allergenic from nonallergenic food extracts. Data presented using a mouse model
suggest that pepsin resistance is indicative of allergenicity. Certain
questions remain to be addressed before considering animal model
validation. Gel-free mass spectrometry is a viable alternative to more
labor-intensive approaches to quantitative proteomics. Proteomic
data presented on four nontransgenic varieties of soy suggested that
if known allergen expression in genetically modified crops falls
within the range of natural variability among commercial varieties,
there appears to be no need to test further. Finally, basic research
continues to elucidate the etiology of food allergy.
Disclaimer: This paper has been reviewed by the National Health and
Environmental Effects Research Laboratory, U.S. Environmental Protection
Agency, and approved for publication. Approval does not signify that the
contents necessarily reflect the views and policies of the Agency nor does
mention of trade names or commercial products constitute endorsement or
recommendation for use.
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INTRODUCTION

Food allergy is a relatively new concern for toxicologists as
a result of the genetic engineering of novel proteins into food crops
in order to promote resistance to herbicides, pests or other stresses,
improve nutrition, or otherwise modify the plant phenotype.
Allergic reactions to food are relatively rare. The incidence of food
allergy in the United States and other ‘‘westernized’’ countries
ranges from 1 to 2% in adults and 6 to 8% in children (GAO, 2002;
Ladics et al. 2003). Relatively few foods are responsible for the
vast majority of significant food-induced allergic reactions
although what makes them unique is not entirely clear. Food
allergy can manifest as inflammation of the skin (hives), gut, and/
or lung, and in the most extreme cases (three individuals per
100,000/year) can result in anaphylactic shock and death (Burks
and Sampson, 1997). The responses are most commonly associated with production of protein-specific immunoglobulin E
(IgE). Thus, although transgenic modification of crops has many
advantages over more conventional approaches, there is some
concern that introduction of a novel protein into the food supply
could increase the risk of food allergy in susceptible individuals.
There are three possible scenarios: (1) transferring an existing
allergen or cross-reactive protein from one crop to another, (2)
creating food allergens de novo, or (3) altering or quantitatively
increasing an endogenous (existing) allergen (i.e., increasing
exposure to known food allergens). In addition to genetic
engineering, conventional breeding approaches, such as chemical
and radiation mutation, can also alter levels of existing proteins
and may pose a potential risk (Batista et al., 2008).
Over the last 12 years, several guidance documents have
been written to provide recommendations for assessing the potential allergenicity of transgenic proteins (Codex Alimentarious
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Commission, 2003; FAO/WHO, 2001; Metcalfe et al., 1996).
Updates occurred with each successive document; however, there is
no single, definitive test for determining the allergenic potential of
novel proteins. Therefore, the U.S. agencies responsible for the
regulation of foods derived from modern biotechnology use
a ‘‘weight-of-evidence’’ approach. This approach is consistent with
the Annex to the Codex Alimentarius ‘‘Guideline for the Conduct of
Food Safety Assessment of Foods Derived from RecombinantDNA Plants’’ (henceforth, referred to as Codex [Codex Alimentarious Commission, 2003; Ladics, 2008]). The recommended
assessments include consideration of the source of the introduced
protein (i.e., whether the gene source for the new protein is known
to induce allergy), the host crop’s propensity to cause allergy,
similarity of the introduced protein to known allergens (in silico
amino acid sequence similarity comparisons to known human
allergens), physicochemical properties (e.g., susceptibility to acid
and enzymatic digestion in vitro, heat stability), and protein
abundance in the crop. When appropriate (i.e., a positive amino acid
sequence match to a known allergen is observed or the transgenic
protein is derived from a known allergenic source), specific IgE
binding studies are considered. These studies require the use of
well-characterized sera from individuals known to be allergic (or
skin prick test positive) to the identified source and present
ongoing challenges in terms of standardization of test materials,
lack of available sera, and validation of procedures. Codex also
recognized that certain methods previously recommended (e.g.,
animal models; targeted serum screening) were not validated but
may prove useful in the future in assessing the allergenic potential of
transgenic proteins ‘‘as scientific knowledge and technology
evolves’’ (Codex Alimentarious Commission, 2003).
Over the past few years, the U.S. Environmental Protection
Agency (EPA), Health Canada, and industry have funded
research in an effort to increase the scientific knowledge and
technology available to assess the potential allergenicity of
transgenic proteins, and a 2008 joint EPA and National
Institute of Allergy and Infectious Disease (NIAID) exploratory research initiative has recently focused on basic
mechanisms of food allergy. On 15–16 October 2008, industry,
academic, and government scientists gathered in Washington,
DC, at a meeting sponsored by the Health and Environmental
Sciences Institute (HESI) of the International Life Sciences
Institute, to review the results of this new research and consider
its implications and applications as well as to discuss additional
research and validation needs. Research in four areas was
considered: use of protein structure to predict allergenicity,
serum screening, newly developed animal models, and use of
proteomics to assess the amount of allergenic protein in plants.
The final session described some of the new research projects
recently funded by the joint EPA/NIAID initiative.

structural attributes could prove valuable for assessing
allergenic potential. Early guidelines proposed linear bioinformatic searches using 8–12 contiguous amino acids in common
with a known allergen as an indicator of potential allergenic
risk based on sequence similarity (Metcalfe et al., 1996).
However, the use of a six-amino acid sliding window was later
recommended (FAO/WHO, 2001) but was subsequently found
to yield an unacceptably high number of false positives
(Hileman et al., 2002; Silvanovich et al. 2006; Stadler and
Stadler, 2003). It was concluded that using greater than 35%
shared identity over any 80 amino acid section (based on
FASTA or other equivalent programs) is a highly conservative
estimate (i.e., many false positives) of the potential for crossreactivity (Ladics et al., 2007; Thomas et al., 2005a). FASTA
(Pearson et al., 1988) is a program used for amino acid
sequence (or nucleotide) comparisons and database searches.
Hence, although these sequence analogy approaches are useful,
it is likely that many potentially beneficial protein products are
unnecessarily eliminated early in the evaluation process.
Additional approaches to sequence/structure analysis would
be welcome.
Dr Werner Braun presented information on a structural
database of allergenic proteins (SDAPs) (http://fermi.utmb.edu/
SDAP/) that is integrated with a variety of computational tools
(Table 1). In addition to the above-mentioned FASTA and
short amino acid sliding window approaches, several additional
types of structural analyses are available at this web site. All
allergens in SDAP are classified into their closest protein
families as defined by the Pfam database of information about
protein domains and families (http://pfam.sanger.ac.uk/).
Allergens are found in only a small subset of all known
protein families (Radauer et al. 2008). However, protein
families that contain allergens also include hundreds of nonallergenic proteins. Using SDAP tools, sequence motifs unique
to the allergens in three families (storage proteins, Bet v 1, and
TABLE 1
Tools Available for Assessing Potential Allergenicity Based
on Structural Analyses
Structural
characterization
35% shared identity
over any 80 amino
acids
Protein families
PD

http://www.ebi.ac.uk/
Tools/webservices/
services/fasta
http://pfam.sanger.
ac.uk/
Ivanciuc et al. (2009b)

3D structure

Oezguen et al. (2008)

PROTEIN STRUCTURE

There are currently no known unique motifs that identify
a protein as an allergen; however, a better understanding of

Sourcea

a
b

Comments
Current approach; highly
conservative
Allergens limited to a small
subset of familiesb
Based on physicochemical
propertiesb
Conformation of epitope
is important; 433 reliable
3D modelsb

All may be accessed at http://fermi.utmb.edu/SDAP/.
Add value to current approach.
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tropomyosin) were found to overlap with known IgE epitopes
(Ivanciuc et al., 2009a), suggesting that such motifs might be
useful is separating non-allergenic from allergenic members
within protein families. Another tool available in SDAP is the
computation of property distance (PD) values for measuring
peptide similarity. A protein sequence similarity search is
based on the five-dimensional descriptors E1–E5 of amino acid
properties derived from a pool of 237 physicochemical
properties. The similarity between two sequences A and B,
each one consisting of N residues, is the PD.

The greatest research need in this area is to identify
additional sequences of allergenic IgE epitopes (Bannon and
Ogawa, 2006). Also needed is a comparison of 35 vs. 50% or
greater homology over 80 or greater amino acids for crossreactivity using well-characterized patient allergic serum
because, as noted above, the 35% homology is a highly
conservative and 50% might be a better indicator.

"
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A ‘‘specific’’ serum screen involves testing a protein of
interest with sera from patients with documented clinical food
allergy to a specific allergen to confirm that the tested protein is
not cross-reactive with the protein to which the patient
produces IgE antibodies. A ‘‘targeted’’ serum screen involves
testing the protein of interest with sera from patients sensitive
to food or aeroallergens from the same broad group. In either
case, the principles associated with the assays used are similar.
As noted above, the Codex recommendations include specific,
but not ‘‘targeted,’’ serum screening as part of the weight-ofevidence approach to identifying potential allergens. However,
practical guidance on how to conduct either of these tests has
been lacking. Issues associated with obtaining and validating
sera for such tests have been previously described (Thomas
et al., 2007a). Dr Richard Goodman presented results from
a grant to develop a comprehensive strategy and model
protocols to evaluate IgE binding and the range of IgE binding/
cross-reactivity.
Serum IgE tests must be reproducible, sensitive, and specific.
This begins with documentation that the serum donor is indeed
allergic to the allergen of interest. A positive response to oral
food challenge is the most definitive test for specificity, but this
test is often not performed for practical or ethical reasons.
Careful clinical history and positive skin prick tests results are
viable alternatives for establishing specificity. If serum from
different donors is pooled, it is important to characterize the
individual sera to understand the similarities or dissimilarities.
Otherwise one serum sample could dominate the results or
dilute out IgE that is present in low abundance. Dr Goodman
has collected a large set of well-characterized sera specific for
a variety of food allergens. One of the most difficult parts of
this experimental approach is the accessibility to enough
specific donor sera.
An appropriately validated IgE assay is also essential to the
success of any particular serum screening effort. A number of
issues must be addressed to ensure the integrity of the assay
including appropriate blocking agents to prevent nonspecific
binding, overcoming the much larger higher concentrations of
IgG relative to IgE that are generally present in sera and can
interfere with IgE detection, and demonstrating specificity of
the anti-IgE component (secondary antibody) in the ELISA
(Holzhauser et al., 2008). A variety of approaches are possible
including ELISA and dot and Western blots. It is best to

The PD index is a statistically validated method to detect
discrete regions of proteins that have a high probability of
cross-reacting with IgE from allergic patients (Ivanciuc et al.,
2009b). Finally, the SDAP Web site provides the means to
examine similarities to allergenic proteins with respect to threedimensional (3D) structure. 3D structures are available in the
Protein Data Bank for only 5% (45/829) of all allergens
catalogued in the SDAP. To overcome this limitation, an
automated procedure was used to prepare 3D models of all
allergens where there was no experimentally determined 3D
structure or high identity (95%) to another protein of known
3D structure. After a final selection using quality criteria, 433
reliable 3D models were retained and are now available from
the SDAP Web site (Oezguen et al., 2008).
From the preceding, it is clear that several new approaches
are available that might be useful in the development of more
refined bioinformatics analyses for determining food safety
(Table 1). Significant progress has been made since 2005 when
application of in silico methods to predict allergenicity was the
topic of an HESI workshop (Thomas et al., 2005a). Using the
SDAP, it would be possible to use a tiered or weight of
evidence approach to protein structure analysis that could
provide a more accurate identification of potential allergens
than the current, highly conservative, approach. This could
include assessing potential allergens according to protein
families, PD, and 3D structure in addition to the sliding
window analysis of amino acid sequence and FASTA. Further
discussion between scientists and the regulatory community are
needed to determine the best use of these new in silico tools.
Dr Catherine Schein presented plans for a newly funded
grant that will test the hypothesis that computational tools
developed as part of the SDAP can detect IgE epitopes
responsible for cross-reactions among distantly related nut
proteins, according to their common physicochemical properties. She intends to test whether the affinity of the IgE/protein
epitope interaction is consistent with clinically relevant crossreactivity among nuts. Results from this grant should further
substantiate the use of structural tools that have been
developed.

SERUM SCREENING
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confirm results using more than one approach. Generally, IgE
binding to carbohydrate domains is irrelevant to clinical
allergy, unless there are multiple carbohydrates on the
potentially allergenic protein (Altmann, 2007). However,
because posttranslational modifications (such as glycosylation)
may contribute to allergenic potential of a protein, more work
is needed on cross-reactive carbohydrate determinants in order
to establish criteria for when and how to exclude such results.
Competitive inhibition tests can be used to establish specificity
of serum and to rule out carbohydrate effects on IgE binding.
Well-characterized positive and negative controls should be
included in all assays, a challenge in itself. More details on key
factors of experimental design and methodology for serum IgE
tests, especially strategies to minimize false negatives and false
positives, are published elsewhere (Goodman, 2008).
Dr Goodman’s experience is that these in vitro tests can over
predict allergy. A major uncertainty is how much in vitro crossreactivity is required to trigger allergic reactions. It is difficult
to verify biological relevance (allergy) when subjects are not
available for challenge tests. For this reason, Dr Goodman
proposed to utilize the rat basophilic leukemia (RBL) line 30/
25, transfected with the human IgE receptor, to further develop
an assay for testing human allergic sera described by Ladics
et al. (2008). Because this approach assesses antibody binding
to basophils and release of mediators, it may provide the means
to demonstrate biologically relevant allergenic activity when
food challenge or skin prick testing of human subjects is not
possible. Due to the considerable effort associated with
obtaining adequate amounts of appropriate sera and validating
assays, conducting meaningful serum screening is still
extremely challenging. Without rigorous attention to detail,
there is great potential for generating data that may not be an
accurate prediction of allergenicity.

MOUSE MODELS OF FOOD ALLERGY

The desire for an animal model that could be used to
establish the relative allergenicity of a transgenic protein as
compared to conventional food proteins has been recognized
since the first discussions on safety assessment of transgenic
proteins (Metcalfe et al., 1996). As with any toxicity assessment, an appropriate animal model should produce sensitization and/or elicitation of allergic symptoms at a physiologically
relevant dose, via the relevant route of exposure (generally
thought to be ingestion) in a standard (readily available) mouse
strain. However, oral tolerance is a major barrier to developing
such an ideal model. In mice, as in most humans, the immune
response to an ingested protein (that survives digestion in
the stomach) is an active process (oral tolerance) that blocks
the development of IgE and delayed-type hypersensitivity
responses (Strobel and Mowat, 2006). Five investigators
presented work on six new mouse models. (See Table 2 for
a summary and comparison of these models.) All but two

involve the use of adjuvant at the time of sensitization to
circumvent oral tolerance, and all but one used the oral route of
sensitization. Earlier attempts to develop a model using ip
sensitization have been discussed elsewhere (Dearman et al.,
2003; Thomas et al., 2005b) and were only briefly mentioned
at the current meeting.
Dr Venu Gangur described a model that sensitizes mice to
food extracts by transdermal exposure. Although not thought to
be the principal route of exposure, data suggest humans can be
sensitized through the skin (Lack et al., 2003). Food extract
was applied weekly for 6 weeks followed by oral challenge and
observation for anaphylactic end points. IgE levels were also
assessed (Birmingham et al., 2007; Navuluri et al., 2006).
Using this model, it was possible to distinguish between
allergenic food extracts and non-allergenic extracts with the
exception that two non-allergenic extracts appeared to have
sensitizing (IgE inducing) potential, but neither produced an
elicitation response following the oral challenge.
Three investigators, Drs Christal Bowman, Harm HoganEsch, and David Lefebvre described variations of a mouse
model originally developed to study peanut and milk allergies
(Li et al., 1999, 2000) and recently applied (Bowman and
Selgrade, 2008a) to assess the relative allergenicity of various
food extracts. Mice were sensitized with two doses of food
extract (in the 1–5 mg range), orally, 1 week apart, with cholera
toxin as adjuvant, and specific IgE was assessed 1 week after
the second dose. Two of the three investigators were able to
distinguish between allergenic and non-allergenic food extracts
based on the IgE response. The A/J mouse appeared to be the
most sensitive mouse strain, but the C3H/HeJ mouse produced
similar results.
Dr Paul Bryce described an oral exposure model that used
a much lower sensitizing dose (0.1 mg) given on eight
consecutive days using staphylococcal enterotoxin B (SEB)
instead of cholera toxin as the adjuvant (Ganeshan et al., 2009).
In addition to measuring antigen-specific IgE, a challenge dose
without adjuvant was administered 24 h after the last
sensitization, and various physiologic and immunologic end
point characteristic of anaphylaxis were assessed. This model
gave promising results for peanut extract and ovalbumin;
however, as yet, neither non-allergenic food extracts nor nonallergenic proteins have been tested in this model. It should
be noted that previous attempts to validate a model that
employed the ip route of exposure were thwarted by mixed
results in that some investigators observed positive responses
to purportedly non-allergenic proteins (Herouet-Guicheney
et al., 2009; Thomas et al., 2005b). Also, in the Bowman
model, non-allergenic food extracts began to show significant
increases in specific serum IgE at high doses when the
sensitization regimen was extended to 4 weekly exposures
(Bowman and Selgrade, 2008a). This observation suggests
that it is important to test non-allergenic food extracts in the
Bryce model, which has a longer sensitization time, albeit
with lower doses.
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TABLE 2
Summary of Mouse Models

Investigator
Gangura

Mouse strain
BALB/c

Sensitization route
(mg/mouse/dose)
Dermal (0.05, 0.5, 1), six
dose at weekly interval

Adjuvant

Challenge route
(mg/mouse)

None

Oral (13)

End points
IgE
Symptoms score

Temperature

Bowmand

C3H/HeJ

Oral (1, 2, 5), two doses at
weekly interval

CT

None

IgE

Bowmane

C3H/HeJ

Oral (1, 2), one dose

None

ip (0.1)

IgE

Lefevbre

C3H/HeJ

Oral (2), two doses at weekly
interval

CT

None

IgE

HoganEsch

A/J
BALB/cJ
C3H/HeJ

Oral (1), six doses over 3 weeks

CT

None

IgE

Brycef

BALB/c or C57BL/6

Oral (0.1), eight doses at daily
interval

SEB

Oral (5)

IgE
Symptoms score
Physiologyg
Eosinophils
Mast cell degranulation

Food extracts or
allergens
Hazelnutb
Cashewnutb
Sesameb
Eggb
Milkb
Shellfishb
Amaranth seedb
Kidney beanc
Pinto beanc
Blueberryc
Peanutb
Brazil nutb
Egg whiteb
Turkeyc
Spinachc
Peanutb
Brazil nutb
Egg whiteb
Ovalbuminb
Turkeyc
Spinachc
Peanutf
Hazelnutb
Potatoc
Spinachc
Peanutf
Ovalbuminb
Spinachc
Potatoc
Ovalbuminb

Peanutb

Note. CT, cholera toxin.
a
Birmingham et al. (2007).
b
Known food allergens.
c
Not thought to be food allergens.
d
Bowman and Selgrade (2008a).
e
Bowman and Selgrade (2008b).
f
Ganeshan et al. (2009).
g
Temperature, blood pressure, and plethysmography.

The last oral exposure model presented assessed the
induction of oral tolerance rather than sensitization because
an allergic response requires the ability to sensitize as well as to
avoid the induction of oral tolerance. Mice were fed a single
dose of vehicle or food extract without adjuvant and challenged
1 week later by the ip route with the food extract of interest.
Significantly lower IgE levels in mice that received the oral
food extract exposure versus vehicle were considered to be
indicative of oral tolerance, which mitigates allergenicity
(Bowman and Selgrade, 2008b). Also related to tolerance, Dr
HoganEsch presented data (unpublished) using mice deficient

in TCR delta gamma–positive T cells, which are thought to be
important in the induction of oral tolerance. However, oral
administration of allergenic food extracts (without adjuvant) to
mice lacking this receptor did not lead to the expected
induction of IgE antibodies.
Predictions of allergenicity based on Bowman’s mouse
model appear to be consistent with predictions based on
resistance to pepsin digestibility and lend credence to the use of
data from digestibility assays in decision making. Pepsin
(stomach digestion enzyme) stability is clearly important for
sensitization (Bowman and Selgrade, 2008a), but resistance to
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both pepsin and trypsin (intestinal digestion enzyme) appears
to be required for oral tolerance (Bowman and Selgrade,
2008b). Thus, proteins that escape pepsin digestion in the
stomach but undergo trypsin digestion in the gut may pose
more of a risk than those that escape both pepsin and trypsin
digestion because they can induce sensitization, but not
tolerance. Altering digestibility, pH, and/or solubility of the
sensitizing food extract can change the results obtained in the
oral animal models (Bowman and Selgrade, 2008b), suggesting
that the matrix in which proteins are presented can affect
results. Others have drawn similar conclusions (Foss et al.,
2006; Mills and Mackie, 2008; Thomas et al., 2007b). In fact,
it has been suggested that purified peanut allergens possess
little intrinsic immune-stimulating capacity in contrast to
a whole peanut extract (van Wijk et al., 2005). The role of
the food matrix requires further study. From some regulators’
point of view, it would be desirable to test purified, bacterialexpressed, transgenic proteins because the transgenic protein,
not the food crop, is regulated. However, this may not
adequately mimic real world exposure. Whereas, availability of
transgenic crop extracts is limited, for positive and negative
controls extracts are more easily obtained than purified
proteins.
There was general agreement that significant progress has
been made toward developing animal models, but that none of
the currently available models are ready for validation. More
work is needed on identification of appropriate end points,
particularly those that reflect anaphylactic activity. It would be
especially useful to understand the relationship between IgE
levels and some of the manifestations of disease, an ongoing
issue for all atopic diseases. It will also be important to resolve
the role that matrix plays before designing a validation study.
Research is needed to compare the allergenicity of food
extracts versus the purified allergens and, if necessary, to
devise a representative food matrix. In addition, before
validation can be considered, decisions have to be made
regarding which mouse strains and adjuvants to include, as
well as the ideal doses of test materials. Appropriate test
substances that represent a range from highly (commonly)
allergenic to poorly (rarely) allergenic need to be selected. The
goal of animal testing should be to establish a spectrum of food
allergy potencies (conceptualized for food extracts in Fig. 1) or
for specific food proteins and then determine where in that
spectrum transgenic foods (or novel proteins) fit. Especially
when IgE is used as the end point, the goal should not be to
show no response but to show a response no greater than that
associated with most non-allergenic foods and/or proteins.

PROTEOMICS

Proteomics is a rapidly progressing technology used for
a wide range of applications (Canovas et al., 2004; Jorrin et al.,
2007). This session considered the use of proteomics to assess

FIG. 1. Conceptualized spectrum of allergenic potency of food extracts
based on perceived allergenicity in humans (adapted from Kimber, unpublished
data).

the possibility that biotechnology could alter the amount of
existing (endogenous) protein allergens in food crops.
Quantitative proteomics is technologically challenging. Therefore, work was presented comparing three analytical methods:
antibody-based—ELISA/Western blot, SDS-polyacrylamide
gel electrophoresis/2-dimensional gel electrophoresis (2DGE), and liquid chromatography (LC)/mass spectrometry.
The main limitation of the ELISA/Western blot approach is
access to validated methods, reagents, and standards, similar to
the problems encountered in serum screening. The 2-DGE
method has been found to be an effective approach (FAO/
WHO, 2001; Ruebelt et al., 2006) as presented by Dr Corrine
Herouet-Guicheney. This proteomics profiling approach may
detect potential alterations with regards to the amount and/or
expression of protein without the use of antibodies or human
sera. Data were presented, suggesting that LC/mass spectrometry may be a viable, less labor intensive alternative (http://
biochem.missouri.edu/faculty/). Dr Jay Thelen presented data
on variation in the profile of major seed allergens in four nontransgenic varieties of soy planted in seven different regions.
There was a fair amount of natural variability, probably
because many variables including genetic background, climate,
nutrient availability, and other factors can affect the amount of
protein present in a crop. It was concluded, regardless of the
method used to quantify protein, that as long as allergen
expression in genetically modified crops falls within the range
of natural variability, there should be no exposure concerns or
need to test further. Thus, it is important to determine the
natural variation range of protein allergen levels in nongenetically modified crop species before any of these methods
can be utilized to evaluate protein levels in genetically
modified crops. It is currently impossible to correlate protein
expression with biological relevance because of limited data on
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quantitative thresholds for sensitizing individuals to most
allergens.
BASIC RESEARCH

Plans for three recently funded grants from the joint NIAID/
EPA initiative were described in the final session of the
meeting. Dr Cecilia Berin described plans to use a mouse
model to understand the role of thymic stromal lymphopoietin
(TSLP) in food allergy. TSLP is an epithelial-derived cytokine
that has a central role in the development of allergic
inflammation in the skin and lung. The hypothesis to be tested
is that overexpression of TSLP promotes allergic sensitization
to food allergens. In addition to identifying risk factors that
may explain individual susceptibility to food allergy, results of
this grant could provide additional end points to be assessed in
mouse models and could also lead to the development of
a transgenic mouse that overexpresses TSLP and, hence, is
more susceptible to food allergy.
The goal of the grant presented by Dr Anne Sperling is to
determine whether allergen-specific IgG contributes to the
cellular and molecular processes involved in generating food
allergy. There is growing evidence that IgG may play a role in
food allergy and other atopic diseases (Lau et al. 2005; Leung
et al. 2003; Sicherer and Sampson, 2007). The anaphylactic
reactions elicited in mice following sensitization with cholera
toxin differ from those observed in the SEB model (described
above) in that the latter exhibits a late-phase airway response
that is not seen with cholera toxin–driven sensitization
(Ganeshan et al., 2009), as well as greater eosinophilia and
plasma histamine. Both models promote equivalent levels of
antigen-specific IgE. However, cholera toxin promotes both
IgG1 and IgG2a, whereas SEB promotes only IgG1. Hence, the
investigators hypothesize that mast cells and macrophagemediated responses during anaphylaxis are altered by activation via the IgG receptor and that the differences in IgG1 and
IgG2a production between cholera toxin and SEB-driven
sensitization underlie the differences in anaphylactic responses
observed. Others have demonstrated in vitro activation of
human mast cells with IgG1 (Woolhiser et al., 2003). Clearly,
the results of this work could influence adjuvant selection for
mouse models, in addition to increasing our understanding of
the role of IgG subclasses in food allergy.
The final presentation, by Dr Fred Finkelman, also focused on
the elicitation (anaphylactic) response, specifically to peanut
allergens and the roles played by innate immunity and
complement (C). The investigators intend to test the following
hypotheses: (a) peanuts have components that induce shock
primarily by causing the production of C-derived anaphylatoxins
that induce macrophages and mast cells to produce plateletactivating factor and histamine; (2) the C3-related anaphylactoid
response may act synergistically with peanut-induced IgEmediated mast cell degranulation to induce the severe anaphylaxis
experienced by some peanut-allergic patients; and (c) the inflam-

matory response stimulated by peanut components acts as an
adjuvant that promotes the induction of a Th2 response to the
major peanut allergens. The investigators theorize that similar
responses may occur with tree nuts, but not milk or egg white.
A better understanding of the elicitation response may suggest
other end points that may be more predictive of anaphylaxis
than IgE and provide a better understanding of the structural
components of peanuts and tree nuts that cause them to be potent
food allergens. Through the joint exploratory research initiative,
NIAID also funded several other grants that were not discussed at
this meeting.
SUMMARY

The studies presented here provide support for current
approaches used to assess the allergenic potential of transgenic
proteins (which are highly conservative, but effective) and also
provide new tools that could be quite useful for safety
assessment. More sophisticated structure-activity tools may
prevent the unnecessary elimination of potentially useful
products early in the development process. More detailed
protocols for serum testing have been developed that should be
applied so that the data generated are reliable as there are many
pitfalls that can lead to inaccurate prediction of allergenicity
using this approach. LC/mass spectrometry may be a viable
alternative to more labor-intensive approaches to quantify
proteins. Progress has also been made with animal models; data
generated using the Bowman mouse model suggest that pepsin
digestibility is a good indicator of potential allergenicity.
Animal research also suggests that the food matrix may play an
important role in the sensitization process. All the above rely
heavily on IgE as the indicator for potential allergenicity.
Because it is possible for IgE responses to occur in the absence
of an adverse reaction in both humans and mice, basic research
is currently underway to better understand the cofactors that
contribute to anaphylactic/systemic reactions and potentially
help to refine our approaches to safety assessment in the future.
Likewise research underway to better understand oral tolerance
may help to refine future safety assessments. To date, assessments have largely focused on the sensitization process, but
work presented here suggests that the ability to sensitize and
the ability to evade oral tolerance are not one and the same.
Pepsin stability is clearly important for sensitization, but
resistance to both pepsin and trypsin appear to be required for
oral tolerance. Research on food allergies in general is
receiving more attention from the scientific community because
of targeted research initiatives, which should result in a better
understanding of the disease and all of its causes.
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